The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives

Mass General Brigham

Status and phase

Withdrawn

Phase 4

Conditions

Major Depressive Disorder

Anxiety

Comorbidity

Treatments

Drug: Vilazodone

Drug: Citalopram

Study type

Interventional

Funder types

Other

Identifiers

NCT02028026

VII-IT-10

2013P000335 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to determine whether vilazodone is more effective than citalopram for the treatment of anxious depression. We will use neuroimaging to see whether there are changes in the brains of patients receiving the drug vilazodone that are different from those of citalopram. These changes may show that vilazodone affects the brain differently than most other kinds of standard antidepressant medications.

Full description

This study proposes to utilize recent advances in magnetic resonance spectroscopy (MRS) techniques that permit reliable measurement of Glu in humans (9) to examine whether Vilazodone and citalopram exert differential effects on Glutamatergic neurotransmission in the ACC of anxious unipolar depressed patients. Functional connectivity as measured by Blood Oxygen Level Dependent (BOLD) MRI will be assessed to determine the relationship between the change in connectivity and the change in Glu levels with treatment. We also propose to examine, in an exploratory fashion, the relative effect of the two drugs on BOLD activation in the insula cortex.

Sex

Female

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Female, aged 18-50 years.
Meets DSM-IV criteria for unipolar major depression.
MADRS score > 20.
Subject exhibits clinically significant anxiety and HAM-A score > 15.
Capable of providing informed consent.
Has an established residence and phone.

Exclusion criteria

A clinically significant medical condition which could impact the response of the individual to antidepressant treatment (e.g. diabetes, cancer, lupus or other autoimmune illness). Stably treated hypothyroidism (TSH < 2) will be permitted.
Beta blockers, antidepressants, antipsychotics, lithium, antiepileptic medications, steroids (oral and inhaled), chronic use of nonsteroidal antinflamatory medications (infrequent sporadic use permitted), or other medications with the potential to interfere with the antidepressant effects of Vilazodone.
Pregnancy.
In women of childbearing potential an unwillingness to use reliable methods to prevent pregnancy.
History of manic or psychotic symptoms.
History of seizure or epilepsy.
History of alcohol or drug dependence and active use of substances in the past month.
Active alcohol or drug abuse.
Ingestion of 4 or more caffeinated beverages a day, on average.